Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT3306 versus EU- and US-Keytruda with chemotherapy in stage IV non-small cell lung cancer
CTR20241959Phase 3Terminated
- Sponsor
- BeiGene
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by BeiGene. Started Jun 2024; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20241959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241959.